MARKET

CMRX

CMRX

Chimerix
NASDAQ
1.010
+0.037
+3.85%
After Hours: 1.010 0 0.00% 19:43 12/01 EST
OPEN
0.9797
PREV CLOSE
0.9726
HIGH
1.010
LOW
0.9560
VOLUME
166.08K
TURNOVER
0
52 WEEK HIGH
2.395
52 WEEK LOW
0.8800
MARKET CAP
89.78M
P/E (TTM)
-1.0515
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CMRX last week (1120-1124)?
Weekly Report · 11/27 10:41
Chimerix: Statement of changes in beneficial ownership of securities
Press release · 11/20 22:02
Weekly Report: what happened at CMRX last week (1113-1117)?
Weekly Report · 11/20 10:40
Chimerix: Initial statement of beneficial ownership of securities
Press release · 11/17 01:05
Chimerix: Statement of changes in beneficial ownership of securities
Press release · 11/17 01:04
Chimerix: Current report
Press release · 11/16 22:22
Chimerix names Thomas Riga as Chief Operating and Commercial Officer
Chimerix names thomas riga as chief operating and commercial officer. Cmrx -3.0% premarket to $0.93. Mr. Riga served as president and chief executive officer at spectrum pharmaceuticals, through its acquisition in july. Chimerix announced the appointment.
Seeking Alpha · 11/16 12:18
Chimerix: Statement of changes in beneficial ownership of securities
Press release · 11/14 04:27
More
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Webull offers Chimerix Inc stock information, including NASDAQ: CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.